Title: Update in treatment options for psoriatic arthritis
Authors: De Vlam, Kurt ×
Lories, Rik #
Issue Date: Nov-2009
Publisher: Expert Reviews Ltd.
Series Title: Expert Review of Clinical Immunology vol:5 issue:6 pages:779-788
Abstract: Psoriatic arthritis is a chronic inflammatory joint disease in patients with psoriasis and has a varying disease course. The majority of patients develop important disability and joint destruction within a few years of disease onset, necessitating the initation of disease-modifying therapy. Treatment options for peripheral disease, enthesitis and dactylitis include nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), local steroids and TNF-blocking agents. Axial disease is treated with NSAIDS and TNF blockade. Major clinical response is seen in approximately 30% of patients with methotrexate or leflunomide but no structural effect has yet been documented. Anti-TNF treatment has the best number-needed-to-treat/number-needed-to harm ratio of all DMARDs in psoriatic arthritis and is able to induce clinical remission in at least 30% of patients. TNF-blocking agents have also been demonstrated to slow down or halt radiographic progression.
ISSN: 1744-666X
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Rheumatology Section (-)
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science